Mironid Ltd.

Mironid Ltd. is a UK-based biotechnology company specializing in the development of innovative therapeutic solutions targeting rare diseases through its advanced research and discovery programs. Founded in 2015 and headquartered in Glasgow, UK, Mironid Ltd. focuses on developing therapies for rare diseases.

The company has secured a total of GBP 8. 18 million in funding through its Series A round, led by Roche Venture Fund on March 31, 2023, with participation from notable investors including BioGeneration Ventures and the European Investment Fund. The founders, Miles Houslay and Nigel Pyne, have a history of innovation in the biotechnology sector, contributing to the company’s vision and growth. Currently, Mironid boasts a company valuation of GBP 24.

82 million, with a total of five deals completed. Mironid Ltd. specializes in delivering advanced therapeutic solutions aimed at treating rare diseases. Its primary offerings include cutting-edge investigational medicines developed through rigorous research and scientific collaboration.

The company’s products are designed to address unmet medical needs, particularly for conditions that lack effective treatments. These solutions are aimed at healthcare providers and patients predominantly in Europe and North America, ensuring compliance with regional regulations and standards. In the most recent year, 2024, Mironid Ltd. reported a revenue of GBP 0, with an EBITDA amount of GBP -8,763,838.

40. The company’s revenue model is based on securing investment for its research and development programs rather than generating direct sales at this stage. Looking ahead, Mironid Ltd. plans to utilize the GBP 8.

18 million raised in its Series A funding to expand its patent portfolio and advance its main discovery program through IND-enabling investigations. The company is actively designing new therapeutic products aimed at treating rare diseases, with ambitions to launch these innovations within the next 18 to 24 months. Additionally, Mironid is targeting expansion into North American markets to enhance its presence and reach in the biotechnology sector.